[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL124881A0 - Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer - Google Patents

Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Info

Publication number
IL124881A0
IL124881A0 IL12488197A IL12488197A IL124881A0 IL 124881 A0 IL124881 A0 IL 124881A0 IL 12488197 A IL12488197 A IL 12488197A IL 12488197 A IL12488197 A IL 12488197A IL 124881 A0 IL124881 A0 IL 124881A0
Authority
IL
Israel
Prior art keywords
centchroman
enantiomer
prophylaxis
manufacture
treatment
Prior art date
Application number
IL12488197A
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL124881A0 publication Critical patent/IL124881A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12488197A 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer IL124881A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1000096P 1996-01-11 1996-01-11
DK77696 1996-07-11
PCT/DK1997/000007 WO1997025034A1 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Publications (1)

Publication Number Publication Date
IL124881A0 true IL124881A0 (en) 1999-01-26

Family

ID=26064631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12488197A IL124881A0 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Country Status (12)

Country Link
EP (1) EP0873119A1 (en)
JP (1) JP2001500101A (en)
KR (1) KR19990077157A (en)
AU (1) AU1367197A (en)
BR (1) BR9706966A (en)
CA (1) CA2241462A1 (en)
CZ (1) CZ217198A3 (en)
HU (1) HUP9901633A3 (en)
IL (1) IL124881A0 (en)
NO (1) NO983177L (en)
PL (1) PL328135A1 (en)
WO (1) WO1997025034A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028724A1 (en) * 1997-11-10 2000-08-23 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
AU2011253842B2 (en) * 1998-06-11 2014-08-14 Endorecherche Inc. Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EA014878B1 (en) 2004-10-20 2011-02-28 Эндорешерш, Инк. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EA022760B1 (en) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Use of trans-clomiphene for prevention or treatment of type 2 diabetes in men
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
JP7048505B2 (en) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof

Also Published As

Publication number Publication date
CA2241462A1 (en) 1997-07-17
PL328135A1 (en) 1999-01-18
NO983177L (en) 1998-07-10
KR19990077157A (en) 1999-10-25
WO1997025034A1 (en) 1997-07-17
HUP9901633A2 (en) 1999-10-28
AU1367197A (en) 1997-08-01
BR9706966A (en) 1999-05-04
CZ217198A3 (en) 1998-11-11
EP0873119A1 (en) 1998-10-28
JP2001500101A (en) 2001-01-09
HUP9901633A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
ZA957483B (en) Compounds and methods for the treatment of cancer
EP0942742A4 (en) Therapeutic compositions for treatment of cancer
AU1980995A (en) Methods and compositions for treatment of breast cancer
ZA953256B (en) Skin treatment composition
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL124881A0 (en) Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
HUP9802861A3 (en) Use of calendula glycosides for the treatment of psoriasis
AU5005197A (en) Prophylaxis of breast cancer
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA952121B (en) Skin treatment composition
GB9510162D0 (en) Compositions for the treatment of skin conditions
IL101317A0 (en) New compounds for use in the treatment of cancer
ZA97215B (en) Use of the i-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
EP0755262A4 (en) Composition for the treatment of lung disease
GB9405046D0 (en) Skin treatment composition
HU9700079D0 (en) Topical compositions for the treatment of skin disease
ZA979720B (en) Prophylaxis of breast cancer
EP0460690A3 (en) Use of phenolsulfophthaline derivatives for the treatment of osteoporosis
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis
IL115200A0 (en) Pharmaceutical compositions for the treatment of cancer
IL124488A0 (en) A preparation for the treatment of psoriasis
HUP9801868A3 (en) Use of droloxifene for prevention of breast cancer
PL311159A1 (en) Pharmaceutical composition for treating psoriasis